Literature DB >> 18397216

Chronic high Epstein-Barr viral load carriage in pediatric liver transplant recipients.

Michael Green1, Kyle Soltys, David T Rowe, Steven A Webber, George Mazareigos.   

Abstract

Development of EBV disease and PTLD is usually accompanied by the detection of a high EBV load in peripheral blood. However, many children undergoing primary EBV infection following LTx will maintain chronically elevated EBV loads in the absence of clinical symptoms. To better understand this phenomenon, we retrospectively reviewed the records of children undergoing LTx at our center from 1997 to 2007 to identify chronic high EBV load carriers in this population. A CHL state was defined by the presence of a high load for >50% of samples for greater than or equal to six months following either asymptomatic or complete clinical resolution of EBV disease/PTLD. A total of 35 CHL carriers were identified. Pretransplant serologies were available for 29 of the 35; 22/29 (76%) were EBV negative prior to LTx; eight of these 22 developed their CHL state at the time of their primary EBV infection. Fourteen of the 35 had EBV disease (n = 7) or PTLD (n = 7) prior to development of the CHL state. Only one of 35 CHL carriers developed PTLD or lymphoma while they were a high load carrier. In all, 23/35 resolved their CHL state without apparent sequelae while 11 children continue to be asymptomatic high load carriers. These data provide important information about the outcome of chronic EBV high load carriage in pediatric liver transplant recipients.

Entities:  

Mesh:

Year:  2008        PMID: 18397216     DOI: 10.1111/j.1399-3046.2008.00926.x

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN: 1397-3142


  9 in total

Review 1.  Viral surveillance and subclinical viral infection in pediatric kidney transplantation.

Authors:  Jodi M Smith; Vikas R Dharnidharka
Journal:  Pediatr Nephrol       Date:  2014-08-16       Impact factor: 3.714

Review 2.  Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder.

Authors:  Margaret L Gulley; Weihua Tang
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

Review 3.  Monitoring and managing viral infections in pediatric renal transplant recipients.

Authors:  Patrizia Comoli; Fabrizio Ginevri
Journal:  Pediatr Nephrol       Date:  2011-02-26       Impact factor: 3.714

4.  Chronic high Epstein-Barr viral load carriage in pediatric small bowel transplant recipients.

Authors:  Audrey H Lau; Kyle Soltys; Rakesh K Sindhi; Geoffrey Bond; George V Mazariegos; Michael Green
Journal:  Pediatr Transplant       Date:  2010-01-20

Review 5.  Posttransplant lymphoproliferative disease after pediatric solid organ transplantation.

Authors:  Martin Mynarek; Tilmann Schober; Uta Behrends; Britta Maecker-Kolhoff
Journal:  Clin Dev Immunol       Date:  2013-09-24

6.  Co-infection of Cytomegalovirus and Epstein-Barr Virus Diminishes the Frequency of CD56dimNKG2A+KIR- NK Cells and Contributes to Suboptimal Control of EBV in Immunosuppressed Children With Post-transplant Lymphoproliferative Disorder.

Authors:  Janice K P Lam; Tarik Azzi; K F Hui; Aikha M G Wong; Donal McHugh; Nicole Caduff; K H Chan; Christian Münz; Alan K S Chiang
Journal:  Front Immunol       Date:  2020-06-17       Impact factor: 7.561

7.  Long-lasting chronic high load carriage of Epstein-Barr virus is more common in young pediatric renal transplant recipients.

Authors:  Susanne Westphal Ladfors; Jenny K Lindahl; Sverker Hansson; Per Brandström; Rune Andersson; Marianne Jertborn; Magnus Lindh; Susanne Woxenius; Vanda Friman
Journal:  Pediatr Nephrol       Date:  2019-12-04       Impact factor: 3.714

8.  Epstein-Barr Virus DNAemia and post-transplant lymphoproliferative disorder in pediatric solid organ transplant recipients.

Authors:  Yeh-Chung Chang; Rebecca R Young; Alisha M Mavis; Eileen T Chambers; Sonya Kirmani; Matthew S Kelly; Ibukunoluwa C Kalu; Michael J Smith; Debra J Lugo
Journal:  PLoS One       Date:  2022-10-18       Impact factor: 3.752

Review 9.  Molecular pathogenesis of B-cell posttransplant lymphoproliferative disorder: what do we know so far?

Authors:  J Morscio; D Dierickx; T Tousseyn
Journal:  Clin Dev Immunol       Date:  2013-04-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.